What's happening?

The development of an antibody drug conjugate (ADC) is more unpredictable than that of a small molecule new chemical entity (NCE). As a result, the industry needs to invest in more vital research before conducting expensive clinical programs.

Of course, in a shifting regulatory environment with evolving customer demands, CDMOs must always be thinking about what is next.

Karthik Selvaraju, Arjan Mofers, Paola Pellegrini, Johannes Salomonsson, Alexandra Ahlner, Vivian Morad, Ellin-Kristina Hillert, Belen Espinosa, Elias S. J. Arnér, Lasse Jensen, Jonas Malmström, Maria V. Turkina, Padraig D’Arcy, Michael A. Walters, Maria Sunnerhagen & Stig Linder
  Scientific Reports 9, Article number: 9841 (2019)

Pharmaceutical firms are increasingly interested in developing inhaled and nasal delivery formulations. Among many other benefits, administrating drugs via inhalation can reduce the likelihood of patients experiencing adverse effects.

By acquiring new facilities, CDMOs can add new and complementary capabilities, increase capacity, and expand geographical reach.

There is no substitution for experience when it comes to taking substances from pre-clinical to clinical and then to commercial scale. 

With popularity of online pharmacies rapidly increasing and the pharmaceutical black-market has spread into mainstream society and become a widespread issue.

The Spanish pharmaceutical market has proven to be a key source of growth for Recipharm, since the acquisition of its facilities in both Parets and Leganes.

A drug substance project’s movement from pre-clinical to clinical and then into commercial scale manufacture often presents challenges which can lead to failure.

Many companies underestimated the complexity of implementing serialisation solutions.